None of the four variants in CHEK2 appeared to influence the survival time of the patients with kidney cancer Fig 3 Nor did the have an effect on survival if the data was stratified for age, smoking status, cancer family history, sex and clinical characteristics. This evidence concerns the gene CHEK2 and kidney cancer.